# US 2026/0083702 A1 · Inhalation formulation for treating ipf disease and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083702 A1
- Document ID: US20260083702A1
- Status: Published application
- Kind: A1
- Application number: 19/407,845
- Filed: 2025-12-03
- Published: 2026-03-26
- Earliest claimed: 2023-09-07
- Assignees: Suzhou Inhal Pharma Co., Ltd.
- Applicants: Suzhou Inhal Pharma Co., Ltd.
- Inventors: Kaiqi Shi; Qingzhen Zhang; Fangyan Wang; Xunxun Liu; Riwei Yang; Xiujie Liu; Yingliang Ma; Jingxu Zhu
- Web page: https://patentgrep.com/patent/US20260083702A1

## CPC

- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/69: Boron compounds
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An inhalation formulation for treating an IPF disease. The inhalation formulation is an aerosol inhalation liquid formulation, an inhalation aerosol, a dry powder inhaler or a soft mist inhaler. The inhalation formulation contains an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole, and difamilast. A preparation process for the inhalation formulation is introduced into a conventional formulation. An active component in a conventional oral formulation is prone to being destroyed in the digestive tract, and has low bioavailability, a liver first pass effect, and a slow onset of action. An inhalation formulation capable of significantly alleviating IPF is prepared. Tests prove that the prepared inhalation formulation can effectively increase the bioavailability, and improve the clinical use effect.

## Claims

### Claim 1

A pharmaceutical formulation comprising an active drug selected from the group consisting of apremilast, ibudilast, crisaborole, and difamilast, wherein the pharmaceutical formulation is formulated as an inhalation formulation that increases bioactivity of the active drug for the treatment of an idiopathic pulmonary fibrosis (IPF) disease or condition by decreasing the level of malondialdehyde (MDA) or hydroxyproline (HYP) in lung.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the active drug is apremilast.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the inhalation formulation comprises an aerosol inhalation liquid formulation, an inhalation aerosol formulation, a dry powder inhaler formulation, or a soft mist inhaler formulation.

### Claim 4 (depends on 3)

The pharmaceutical formulation of claim 3, wherein the aerosol inhalation liquid formulation comprises the active drug and a pharmaceutical excipient A.

### Claim 5 (depends on 4)

The pharmaceutical formulation of claim 4, wherein the pharmaceutical excipient A comprises a solvent, a nonionic surfactant, a pH buffer, an osmotic pressure regulator, a complexing agent, or a combination thereof.

### Claim 6 (depends on 5)

The pharmaceutical formulation of claim 5, wherein:
(a) the solvent comprises deionized water;
(b) the nonionic surfactant comprises Tween, Span, polyol, or poloxamer;
(c) the pH buffer comprises acetic acid-sodium acetate, phosphate-sodium phosphate, or citrate-sodium citrate;
(d) the osmotic pressure regulator comprises sodium chloride, propylene glycol, glycerol, or glucose; and/or
(e) the complexing agent comprises EDTA or a salt thereof.

### Claim 7 (depends on 3)

The pharmaceutical formulation of claim 3, wherein the inhalation aerosol formulation comprises the active drug and a pharmaceutical excipient B.

### Claim 8 (depends on 7)

The pharmaceutical formulation of claim 7, wherein the pharmaceutical excipient B comprises a hydrofluoroalkane propellant, a polyethylene glycol surfactant, a co-solvent, or a combination thereof.

### Claim 9 (depends on 8)

The pharmaceutical formulation of claim 8, wherein
(a) the hydrofluoroalkane propellant comprises 1,1,1,2,3,3,3-heptafluoropropane or 1, 1, 1,2-tetrafluoroethane;
(b) the polyethylene glycol surfactant comprises PEG200, PEG400, or PEG1000; and/or
(c) the co-solvent comprises propylene glycol or ethanol.

### Claim 10 (depends on 3)

The pharmaceutical formulation of claim 3, wherein the dry powder inhaler formulation comprises the active drug and a carrier.

### Claim 11 (depends on 10)

The pharmaceutical formulation of claim 10, wherein the carrier comprises lactose, mannose, chitosan, DPPC, DSPC, or a combination thereof.

### Claim 12 (depends on 10)

The pharmaceutical formulation according to claim 10, wherein a ratio of the active drug to the carrier ranges from about 5%: 95% to about 99%: 1% w/w.

### Claim 13 (depends on 10)

The pharmaceutical formulation of claim 10, wherein the active drug comprises a particle size D90 ranging from about 1 μm to about 10 μm, and/or wherein the carrier comprises a particle size D90 ranging from about 3 μm to about 200 μm.

### Claim 14 (depends on 3)

The pharmaceutical formulation of claim 3, wherein the soft mist inhaler formulation comprises the active drug and a pharmaceutical excipient C.

### Claim 15 (depends on 14)

The pharmaceutical formulation of claim 14, wherein the pharmaceutical excipient C comprises a solvent, an additive, a pH adjuster, or a combination thereof.

### Claim 16 (depends on 15)

The pharmaceutical formulation of claim 15, wherein:
(a) the solvent comprises deionized water;
(b) the additive comprises EDTA or a salt thereof; and/or
(c) the pH adjuster comprises citric acid, hydrochloric acid, or sodium hydroxide.

### Claim 17 (depends on 5)

A method of making the pharmaceutical formulation of claim 5, the method comprising:
(a) dissolving the active drug, the osmotic pressure regulator, and the complexing agent in the solvent to arrive at a solution A;
(b) dispersing the nonionic surfactant in the solvent to arrive at a solution B;
(c) mixing the solution A and the solution B to arrive at a mixture; and
(d) adjusting the pH of the mixture to from about 4.0 to about 6.0 with the pH buffer.

### Claim 18 (depends on 8)

A method of making the pharmaceutical formulation of claim 8, the method comprising:
(a) micronizing the active drug to form a micronized active drug;
(b) adding the micronized active drug to an aluminum can;
(c) adding the polyethylene glycol surfactant and the co-solvent to the aluminum can,
(d) sealing the aluminum can with a metering valve;
(e) adding the hydrofluoroalkane propellant to the aluminum can through the metering valve; and
(f) sonicating the aluminum can for 30 seconds.

### Claim 19 (depends on 10)

A method of making the pharmaceutical formulation of claim 10, the method comprising:
(a) micronizing the active drug to arrive at a first component;
(b) mixing the first component with the carrier to arrive at a second component; and
(c) preparing the second component into a dry powder formulation.

### Claim 20 (depends on 15)

A method of making the pharmaceutical formulation of claim 15, the method comprising:
(a) micronizing the active drug to form a micronized active drug;
(b) dissolving the additive in the solvent;
(c) adding the micronized active drug into the solvent in step (b);
(d) adjusting the pH of the solvent in step (c) to from about 2.0 to about 6.0 with the pH adjuster.
